Gestational Diabetes Mellitus
Cross-source consensus on Gestational Diabetes Mellitus from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Risks & contraindications
Comparisons
Other
Highlighted claims
- GDM shares metabolic features with type 2 diabetes, particularly insulin resistance and beta-cell dysfunction. — Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study
- GDM is characterized by more severe insulin resistance and dysglycaemia than the physiological insulin resistance of normal pregnancy. — Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study
- GDM diagnosis in the SiGnal-D study uses International Association of Diabetes and Pregnancy Study Group criteria. — Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study
- Women who had GDM will undergo diagnostic OGTT at 6 to 12 weeks postpartum to screen for diabetes or pre-diabetes. — Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study
- The increasing frequency of pregnancies after age 40 is clinically relevant because sarcopenia prevalence is already non-negligible at that age. — Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study
- The relationship between type 2 diabetes and sarcopenia has been described as bidirectional, suggesting sarcopenia may itself be a risk factor for GDM. — Protocol for a prospective cohort study for the assessment of sarcopenia in gestational diabetes: the SiGnal-D study